Medigene's drug Veregen® receives market authorization notification in Taiwan
04 Junho 2013 - 3:00AM
Medigene AG / Medigene's drug Veregen® receives market
authorization notification in Taiwan . Processed and transmitted by
Thomson Reuters ONE. The issuer is solely responsible for the
content of this announcement.
Martinsried/Munich, 4 June, 2013. Medigene AG
(MDG, Frankfurt, Prime Standard) announces that its drug
Veregen® has obtained
market authorization notification in Taiwan. Market launch of the
ointment by Medigene's marketing partner SynCore, a member of the
Sinphar Pharmaceutical Group, is expected in the second half of
2013.
Veregen® is already
being marketed in the USA (by Fougera), in Germany, Austria and
Switzerland (by Abbott), in Spain (by Bial) as well as in Serbia
(by Pharmanova) and approved in further countries. Market approvals
and the launch in additional countries are pending in 2013.
Medigene has entered into several marketing partnerships for
Veregen® across
Europe, Asia, and America, and is planning to continue this global
licensing strategy to further leverage the product's market
potential.
About
Veregen®: Veregen®, an ointment
used in the topical treatment of external genital warts, contains a
catechin concentrate based on a defined extract obtained from green
tea leaves. Since 2010, Veregen®
(Sinecatechins 15% ointment) has been recommended in the US
Department of Health and Human Services Center for Disease Control
and Prevention's Sexually Transmitted Diseases Treatment Guidelines
as a possible option for treating genital warts. Sinecatechins 10%
& 15% ointment (Veregen®) was recently
also included in the European Guideline for the Management of
Anogenital Warts.
About
SynCore: SynCore Biotechnology Co., Ltd, a joint venture
between Sinphar Pharmaceutical Co., Ltd and the National Health
Research Institute of Taiwan, is focused on the development of new
drugs. Currently, SynCore has five products under development in
different stages of clinical trial. Additionally, SynCore has been
granted the exclusive development and marketing right in Asia for a
new drug for the treatment of dry AMD (age-related macular
degeneration) from MacuCLEAR, an US-based biotech company; the drug
received approval to enter into phase II/III clinical trial in the
US and Taiwan. For further information, please visit
www.syncorebio.com.
About
Sinphar Pharmaceutical: Sinphar Pharmaceutical Co, Ltd
(Taiwan Stock Exchange, symbol: 1734), with subsidiaries in China
and Canada, specializes in the sales and marketing of
pharmaceutical products and dietary supplements as well as contract
manufacture for several global pharma companies such as Johnson
& Johnson, Takeda, Shionogi, and Astellas. Additionally,
Sinphar is one of the major producers of paclitaxel
(Phyxol®) in Asia. It
is also involved in the research and development of botanical new
drugs. Further information can be obtained at: www.sinphar.com.
Medigene
AG (Frankfurt: MDG, Prime Standard) is a publicly listed
biotech company headquartered in Martinsried/Munich, Germany.
Medigene focuses on clinical research and development of novel
drugs against cancer and autoimmune diseases. Medigene is the first
German biotech company to generate revenues from a marketed product
(Veregen®), which is
distributed by partner companies. Medigene also has two drug
candidates undergoing clinical trials, EndoTAG®-1 und
RhuDex®, and is
developing an innovative vaccine technology. For further details,
please visit www.medigene.com
This press release contains
forward-looking statements representing the opinion of Medigene as
of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking
statements made herein. Medigene is not bound to update any of
these forward-looking statements. Medigene® and
Veregen® are
registered trademarks of Medigene AG. Polyphenon E®
is a trademark of Mitsui Norin Co., Ltd. These trademarks may be
owned or licensed in select locations only.
Contact
Julia Hofmann, Claudia Burmester
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com
To unsubscribe from the press
release distribution list, please go to
www.medigene.com/unsubscribe.
Press release as PDF
This
announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the
information contained therein.
Source: Medigene AG via Thomson Reuters ONE
HUG#1706734
Meridian Gold (NYSE:MDG)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Meridian Gold (NYSE:MDG)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
